Molecular Prognostic Prediction By Support Vector Machine Integrated Approach For Local Advanced Nasopharyngeal Carcinoma.

Xiang-Bo Wan,X. Wu,X. Fan,H. Cai,Ming Yuan Chen,Jie Xu,Ming Huang Hong,Quentin Liu
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.5514
IF: 45.3
2011-01-01
Journal of Clinical Oncology
Abstract:5514 Background: Accurate means to refine the prognosis of local advanced nasopharyngeal carcinoma (NPC) will improve the selection of patients for tailored therapy. Here, we addressed this issue by developing a mathematical algorithm, Support Vector Machine (SVM), by integrating pathological multibiomarkers. Methods: Ninety-seven local advanced NPC patients (stage III and IVa) in a randomized controlled trial (RCT), consisting of 48 cases serving as the training set and 49 cases as testing set of SVM models, with a 5-year follow-up were selected and studied. We designed 3 SVM models by selecting the variables from 38 tissue molecular biomarkers and 3 EBV related serological biomarkers. Results: The SVM1 displayed highly prognostic sensitivity (sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy were 88.0%, 81.9%, 62.9%, 95.2% and 83.5%, respectively) by integrating 7 molecular biomarkers (Aurora-A, Beclin 1, Ki-67, N-cadherin, nm23-H1, P27, and TIMP 2). The SVM2 model showed highly prognostic specificity (sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy were 84.0%, 94.5%, 84.0%, 94.4% and 91.8%, respectively) by grouping 12 molecular biomarkers (nm23-H1, Pontin, cyclin D1, N-Cadherin, 14-3-3s, Ki-67, Aurora-A, Bcl-2, Beclin 1, MMP 2, EZH2 and TIMP 2) and 3 EBV related serological biomarkers (EA-IgA, VCA-IgA and AER). The SVM3 model, constructed by combination SVM1 with SVM2, displayed a high prognostic capacity (sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy were 88.0%, 90.3%, 75.9%, 95.6% and 89.7%, respectively). Moreover, Cox multivariate regression analysis confirmed that these 3 SVM models were each the significant independent prognostic model (SVM1, HR: 70.745, P = 0.000; SVM2, HR: 145.080, P = 0.000; SVM3, HR: 113.594, P = 0.000) for overall survival in testing set and overall patients. Conclusions: Our SVM prognostic models designed in the RCT displayed strong power in refining patient prognosis for local advanced NPC, potentially directing future target therapy against the correlated signaling pathways.
What problem does this paper attempt to address?